ArticleNeuro-oncology2026
Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children's Oncology Group study ACNS0331.
Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough survival outcomes for average-risk (AR) medulloblastoma remain excellent, patients experience significant long-term toxicities. To evaluate the effect of therapy dose modifications among children with AR medulloblastoma, we examined the association of cumulative chemotherapy dose with overall survival (OS) and event-free survival (EFS) for patients treated on Children's Oncology Group (COG) study ACNS0331.
methodsA cohort of children enrolled on ACNS0331 (medulloblastoma confirmed by methylation, received standard dose craniospinal radiation, and completed all cycles of chemotherapy) were evaluated for cumulative chemotherapy dose intensity continuously and categorically (≥75% or <75% of planned dose). Cox proportional hazards regression models were used to examine associations of proportion of planned chemotherapy received with outcome. A secondary analysis separately evaluated each of the 4 molecular subgroups: Wnt-activated (WNT), Sonic Hedgehog Activated (SHH), group 3 and group 4.
resultsTwo hundred thirty-five children were followed for a median of 9.3 years (range, 7.0-10.4). Dose intensities of vincristine (VCR) and cisplatin showed the most variability (17% and 23.8% of patients received <75% of expected dosing, respectively). Molecular subgroup remained a significant predictor of outcome (EFS [P = .012] and OS [P = .008]). Cyclophosphamide and lomustine were not examined due to minimal dose variability. No significant differences in EFS or OS were found related to reduced dose intensity for VCR (P = .49 EFS, P = .52 OS) or cisplatin (P = .36 EFS, P = .35 OS) when analyzed independently. There was no difference in the effect of dose reductions by molecular subgroup.
conclusionsModerate dose reductions of at least 25% in VCR and cisplatin do not significantly affect survival in AR medulloblastoma. Effects of larger dose reductions (>50%) or dose reductions in high-risk disease were not studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.